With the approval, zilucoplan becomes the first once-daily subcutaneous complement C5 inhibitor available for adults with generalized myasthenia gravis.
UCB announces U.S. FDA approval of ZILBRYSQ[®] for the treatment of adults with generalized myasthenia gravis FDA approval of ZILBRYSQ® has been granted.